$30.13
+0.82
(+2.8%)▲
Insights on Arcturus Therapeutics Holdings Inc
Revenue is down for the last 2 quarters, 43.37M → 28.21M (in $), with an average decrease of 35.0% per quarter
Netprofit is up for the last 3 quarters, -52.55M → -8.57M (in $), with an average increase of 156.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 44.3% return, outperforming this stock by 35.3%
In the last 3 years, Novo Nordisk A/s has given 242.1% return, outperforming this stock by 267.4%
4.05%
Downside
Day's Volatility :6.01%
Upside
2.05%
41.85%
Downside
52 Weeks Volatility :60.01%
Upside
31.23%
Period | Arcturus Therapeutics Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -7.15% | -0.5% | 0.0% |
6 Months | 34.09% | 5.9% | 0.0% |
1 Year | 8.97% | 3.1% | -1.9% |
3 Years | -18.37% | 14.2% | -21.8% |
Market Capitalization | 811.0M |
Book Value | $10.38 |
Earnings Per Share (EPS) | -1.12 |
Wall Street Target Price | 67.63 |
Profit Margin | -17.82% |
Operating Margin TTM | -59.22% |
Return On Assets TTM | -11.11% |
Return On Equity TTM | -10.83% |
Revenue TTM | 166.8M |
Revenue Per Share TTM | 6.26 |
Quarterly Revenue Growth YOY | -80.80000000000001% |
Gross Profit TTM | 62.9M |
EBITDA | -75.2M |
Diluted Eps TTM | -1.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.35 |
EPS Estimate Next Year | 0.6 |
EPS Estimate Current Quarter | -0.99 |
EPS Estimate Next Quarter | -1.06 |
What analysts predicted
Upside of 124.46%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 15.8M | ↑ 21.2% |
Net Income | -21.8M | ↑ 99.83% |
Net Profit Margin | -138.29% | ↓ 54.42% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 20.8M | ↑ 31.97% |
Net Income | -25.7M | ↑ 18.07% |
Net Profit Margin | -123.72% | ↑ 14.57% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 9.5M | ↓ 54.12% |
Net Income | -71.4M | ↑ 177.45% |
Net Profit Margin | -748.13% | ↓ 624.41% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 12.4M | ↑ 29.56% |
Net Income | -206.9M | ↑ 189.87% |
Net Profit Margin | -1.7K% | ↓ 925.65% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 205.8M | ↑ 1564.82% |
Net Income | 9.3M | ↓ 104.52% |
Net Profit Margin | 4.54% | ↑ 1678.32% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 157.7M | ↓ 23.33% |
Net Income | -29.7M | ↓ 417.95% |
Net Profit Margin | -18.84% | ↓ 23.38% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 13.4M | ↓ 50.66% |
Net Income | -34.5M | ↑ 64.0% |
Net Profit Margin | -258.07% | ↓ 180.42% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 160.0M | ↑ 1097.17% |
Net Income | 117.3M | ↓ 440.13% |
Net Profit Margin | 73.32% | ↑ 331.39% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 79.7M | ↓ 50.18% |
Net Income | 50.8M | ↓ 56.75% |
Net Profit Margin | 63.66% | ↓ 9.66% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.6M | ↓ 88.0% |
Net Income | -52.6M | ↓ 203.54% |
Net Profit Margin | -549.4% | ↓ 613.06% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 43.4M | ↑ 353.49% |
Net Income | -16.2M | ↓ 69.13% |
Net Profit Margin | -37.4% | ↑ 512.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 28.2M | ↓ 34.96% |
Net Income | -8.6M | ↓ 47.15% |
Net Profit Margin | -30.39% | ↑ 7.01% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 44.2M | ↓ 15.04% |
Total Liabilities | 30.6M | ↑ 67.61% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 82.1M | ↑ 85.85% |
Total Liabilities | 56.4M | ↑ 84.42% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 476.5M | ↑ 480.03% |
Total Liabilities | 79.9M | ↑ 41.8% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 392.8M | ↓ 17.56% |
Total Liabilities | 164.6M | ↑ 106.0% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 450.4M | ↑ 14.66% |
Total Liabilities | 180.1M | ↑ 9.4% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 429.4M | ↓ 4.66% |
Total Liabilities | 150.9M | ↓ 16.21% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 293.6M | ↓ 12.87% |
Total Liabilities | 148.0M | ↓ 11.03% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 450.4M | ↑ 53.39% |
Total Liabilities | 180.1M | ↑ 21.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 470.9M | ↑ 4.55% |
Total Liabilities | 141.6M | ↓ 21.36% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 430.6M | ↓ 8.54% |
Total Liabilities | 145.5M | ↑ 2.72% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 457.7M | ↑ 6.27% |
Total Liabilities | 177.6M | ↑ 22.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 429.4M | ↓ 6.17% |
Total Liabilities | 150.9M | ↓ 15.03% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.8M | ↑ 4413.04% |
Investing Cash Flow | 22.1M | ↑ 113.75% |
Financing Cash Flow | 10.2M | ↑ 45.81% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.4M | ↓ 68.95% |
Investing Cash Flow | -818.0K | ↓ 103.7% |
Financing Cash Flow | 41.9M | ↑ 310.69% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -42.9M | ↑ 565.03% |
Investing Cash Flow | -1.7M | ↑ 112.96% |
Financing Cash Flow | 436.1M | ↑ 940.74% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -135.0M | ↑ 215.07% |
Investing Cash Flow | -3.4M | ↑ 95.52% |
Financing Cash Flow | 48.0M | ↓ 88.99% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 32.0M | ↓ 123.69% |
Investing Cash Flow | -7.7M | ↑ 126.83% |
Financing Cash Flow | -2.9M | ↓ 105.95% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -42.4M | ↑ 15.17% |
Investing Cash Flow | -2.2M | ↓ 678.31% |
Financing Cash Flow | -1.2M | ↓ 574.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 160.3M | ↓ 477.92% |
Investing Cash Flow | -354.0K | ↓ 83.81% |
Financing Cash Flow | -2.2M | ↑ 82.95% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -35.9M | ↓ 122.38% |
Investing Cash Flow | -691.0K | ↑ 95.2% |
Financing Cash Flow | -27.4M | ↑ 1125.99% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 50.8M | ↓ 241.64% |
Investing Cash Flow | -354.0K | ↓ 48.77% |
Financing Cash Flow | 94.0K | ↓ 100.34% |
Sell
Neutral
Buy
Arcturus Therapeutics Holdings Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Arcturus Therapeutics Holdings Inc | -9.06% | 34.09% | 8.97% | -18.37% | 334.15% |
Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Arcturus Therapeutics Holdings Inc | 10.3 | NA | NA | -2.35 | -0.11 | -0.11 | NA | 10.38 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Arcturus Therapeutics Holdings Inc | Buy | $811.0M | 334.15% | 10.3 | -17.82% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Federated Hermes Inc
BlackRock Inc
ARK Investment Management LLC
State Street Corporation
Vanguard Group Inc
Sumitomo Mitsui Trust Holdings Inc
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
Organization | Arcturus Therapeutics Holdings Inc |
Employees | 180 |
CEO | Mr. Joseph E. Payne M.Sc. |
Industry | Health Technology |